返回
PegBio Co., Ltd.（02565.HK）價格
02565.HK 股價走勢圖
PEGBIO CO-B (02565.HK)
PegBio Co., Ltd.
HK$70.1
-1.26%
$-0.9
盤中： Jan 19, 09:48:24 HKT
暫無資料Follow-Up Questions
PegBio Co., Ltd. 的關鍵財務報表是什麼？
02565.HK 的關鍵財務比率是什麼？
PegBio Co., Ltd. 的收入按細分市場或地理位置如何劃分？
PegBio Co., Ltd. 是否盈利？
PegBio Co., Ltd. 有負債嗎？
PegBio Co., Ltd. 的流通股有多少？
關鍵數據
前收市價
$70.65
開盤價
$71
當日範圍
$69.6 - $71.4
52週區間
$8.68 - $77
交易量
257.0K
平均成交量
310.0K
每股盈餘 (TTM)
-0.64
股息收益率
--
市值
$19.9B
什麼是 PEGBIO CO-B？
PegBio Co., Ltd. is a biotechnology company, which engages in the research, development and production of innovative drugs in the field of chronic disease treatment. The company is headquartered in Hangzhou, Zhejiang and currently employs 58 full-time employees. The company went IPO on 2025-05-27. The firm's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The firm's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The firm's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).